Return to site

Rophe Pharma’s RPHE-7391 Targets Eicosanoid Formation

Robert Gadimian

· Rophe Pharma
broken image

As head of Perceptive Regulatory Consulting, Robert Gadimian provides actionable pathways toward achieving FDA approval for innovative drugs. In his position as Rophe Pharma head, Robert Gadimian is also engaged in drug formulation efforts spanning conditions such as diabetic foot ulcers and male pattern baldness.

The flagship RPHE-7391 product has potential for treating multiple indications as an irreversible inhibitor of LOX, COX, and P-450 enzymes. Blocking arachidonic acid (AA) from binding to such enzymes, it effectively halts downstream reactions involving AA cascades and the formation of the eicosanoids.

Eicosanoids impact many organs in the body in terms of disease formation and progress. In the case of LOX, conditions range from cancer to asthma; in the case of COX, conditions range from juvenile rheumatoid arthritis to osteoarthritis; and in the case of P-450 conditions range from congenital heart disease to adrenal insufficiency. A current focus of Rophe Pharma is on out-licensing RPHE-7391 and also actively finding partner companies for in-licensing of the drug.